Wei Ruan
Changsha, 410011, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
The BMAL1/HIF2A heterodimer modulates circadian variations of myocardial injury.
Journal: Research square
Published: March 11, 2024
BMAL1-HIF2A heterodimer modulates circadian variations of myocardial injury.
Journal: Nature
Published: February 07, 2024
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges.
Journal: Nature reviews. Drug discovery
Published: November 06, 2023
Hypoxia-adenosine axis as therapeutic targets for acute respiratory distress syndrome.
Journal: Frontiers in immunology
Published: October 30, 2023
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine.
Journal: Nature reviews. Cardiology
Published: May 01, 2023
Preemptive parasternal intercostal nerve block for patients undergoing off-pump coronary artery bypass grafting: a double-blind, randomized, controlled trial.
Journal: Frontiers in cardiovascular medicine
Published: March 17, 2023
The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer.
Journal: Frontiers in immunology
Published: February 11, 2023
HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis.
Journal: Nature communications
Published: January 19, 2023
Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling.
Journal: JCI insight
Published: October 04, 2022
Myeloid hypoxia-inducible factor HIF1A provides cardio-protection during ischemia and reperfusion via induction of netrin-1.
Journal: Frontiers in cardiovascular medicine
Published: June 15, 2022
Last Updated: 09/26/2026